IMMUNITYBIO, INC.
SAN DIEGO, CA

IMMUNITYBIO, INC., previously known as NantKwest, is a pioneering, next-generation clinical-stage immunotherapy company based in San Diego, Florida. Founded on August 25, 2016, and listed on Nasdaq under the ticker symbol NK, IMMUNITYBIO focuses on harnessing the innate power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases, and inflammatory diseases. NK cells serve as a critical line of defense by rapidly identifying and destroying stressed cells, such as those infected with viruses or transformed into cancer cells. IMMUNITYBIO is uniquely positioned in rapidly growing markets with high medical needs due to its extensive genomics and transcriptomics discovery and development engine. With a robust pipeline of multiple clinical-stage immuno-oncology programs, the company is advancing innovative treatments including a phase 2 trial for a rare form of melanoma and plans to initiate a clinical trial targeting NK cells against breast cancer. Under the leadership of CEO Richard Adcock, CFO David Sachs, and Gene Jason Liljestrom, IMMUNITYBIO is committed to transforming medicine by developing 'living drugs' delivered in a bag. These novel NK cell-based therapies aim to bring groundbreaking immune treatments into routine clinical care. The company last filed an annual report on April 29, 2024, for the year 2024, emphasizing its ongoing development efforts and mission to lead as a premier immunotherapy enterprise.